Biology of Blood and Marrow Transplantation
Volume 14, Issue 9, Supplement , Pages 29-36, September 2008

Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program

  • John P. Miller

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
  • ,
  • Elizabeth H. Perry

      Affiliations

    • Memorial Blood Centers, St. Paul, Minnesota
  • ,
  • Thomas H. Price

      Affiliations

    • Puget Sound Blood Center, Seattle, Washington
  • ,
  • Charles D. Bolan Jr.

      Affiliations

    • Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Chatchada Karanes

      Affiliations

    • City of Hope National Medical Center, Duarte, California
  • ,
  • Theresa M. Boyd

      Affiliations

    • American Red Cross, Washington, DC
  • ,
  • Pintip Chitphakdithai

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
  • ,
  • Roberta J. King

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Roberta J. King, MPH, National Marrow Donor Program, 3001 Broadway Street NE, Suite 100, Minneapolis, MN 55413.

Received 23 May 2008; accepted 27 May 2008.

Abstract 

The National Marrow Donor Program (NMDP) has been facilitating hematopoietic cell transplants since 1987. Volunteer donors listed on the NMDP Registry may be asked to donate either bone marrow (BM) or peripheral blood stem cells (PBSC); however, since 2003, the majority of donors (72% in 2007) have been asked to donate PBSC. From the donor's perspective these stem cell sources carry different recovery and safety profiles. The majority of BM and PBSC donors experienced symptoms during the course of their donation experience. Pain is the number 1 symptom for both groups of donors. BM donors most often reported pain at the collection site (82% back or hip pain) and anesthesia-related pain sites (33% throat pain; 17% post-anesthesia headache), whereas PBSC donors most often reported bone pain (97%) at various sites during filgrastim administration. Fatigue was the second most reported symptom by both BM and PBSC donors (59% and 70%, respectively). PBSC donors reported a median time to recovery of 1 week compared to a median time to recovery of 3 weeks for BM donors. Both BM and PBSC donors experienced transient changes in their WBC, platelet, and hemoglobin counts during the donation process, with most counts returning to baseline values by 1 month post-donation and beyond. Serious adverse events are uncommon, but these events occurred more often in BM donors than PBSC donors (1.34% in BM donors, 0.6% in PBSC donors) and a few BM donors may have long-term complications. NMDP donors are currently participating in a randomized clinical trial that will formally compare the clinical and quality-of-life outcomes of BM and PBSC donors and their graft recipients.

Key Words: National Marrow Donor Program, NMDP, Unrelated donor, Bone marrow donor, Stem cell donor, PBSC

 

 STATEMENT OF CONFLICT OF INTEREST: See Acknowledgements on page 36.

PII: S1083-8791(08)00229-2

doi:10.1016/j.bbmt.2008.05.018

Biology of Blood and Marrow Transplantation
Volume 14, Issue 9, Supplement , Pages 29-36, September 2008